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chemotherapy to evaluate the rate of second cancers and their sites 
according to the extension of radiation fields. 
Materials and Methods: From 1990 to 1995, 140 patients (pts) with 
early-stage HL (IA, IB, IIA ± bulky) received 4 cycles of ABVD and then 
they were randomized to receive STNI (36 Gy to involved sites and 30 
Gy to uninvolved sites) or IF (36 Gy to involved sites). The endpoints 
of this review were to assess the rate of late toxicity in term of SPC 
and the spatial relationship between radiation fields extent and SPC. 
We used the topographical criteria defined by Dorr1 to localize SPC 
compared to RT fields. Event-free survival (EFS) and overall survival 
(OS) were estimated by Kaplan-Meier method. Crude and age-adjusted 
incidence rates of SPC were calculated by Poisson regression.  
Results: After a median follow-up of 203 months, 24 SPC were 
observed: 7 cutaneous basal cell carcinomas, 1 MDS, 16 solid tumours 
(11 breast, 2 prostate, 1 ovary, 1 skin, 1 colon). For this study we 
evaluated only solid cancers.  13 SPC were in STNI arm, 3 in IFRT (p 
0.014). Median time to second malignancies was 172 months in STNI 
and 178 in IFRT. IR (incidence rate/1000 person-years) 12.9 in STNI 
and 2.76 in IFRT (p 0.014). In a univariate analysis, the second 
malignancies risk is higher in STNI versus IFRT (hazard ratio 4.40, 95% 
CI). According to the topographic criteria, SPC were located as listed 
below: 
 
 In-field Margin Adjacent Distant
Breast 8 3 0 0 
Other 0 0 2 3 
 
Dose at in-field region was 36 Gy in all cases. 
Median age at breast cancer diagnosis was 43years (27y at HL 
diagnosis); median age at diagnosis of other cancers was 62y (49y at 
HL diagnosis). 7 breast cancers (5 infiltrating carcinoma and 2 in situ) 
were treated with conservative surgery and in 5 cases radiation-
therapy was performed. 2 breast cancer pts died (1 myocardial 
infarction, 1 disease progression). All the remaining pts are alive and 
with no evidence of both tumours. 
Conclusions: Combined modality treatment is currently the treatment 
of choice for early-stage HL. In this setting of patients, RT contributes 
to achieving a high cure-rate. Despite the fact that the optimal size of 
RT fields and dose are still unknown, our data confirm that reducing 
of field size to IF is safe both in terms of cure rate and reduction of 
second cancers. 
1) Dörr W, Herrmann T Second primary tumors after radiotherapy for 
malignancies. Treatment related parameters. Strahlenther Onkol 
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Purpose/Objective: Glioblastoma multiforme (GBM) is the most 
aggressive type of brain cancer in adults. It is suggested that tumour 
microenvironment might influence treatment outcome of cancer 
patients. The aim of this study was to evaluate the impact of 
inflammation on treatment response and survival of GBM patients. 
Materials and Methods: Between Jan 2006 and Dec 2008, 42 patients 
were operated and received postoperative radiotherapy 
(±chemotherapy). Surgically excised GBM tissues were immuno-
histochemically examined for CD63 expression. Since CD63 is 
expressed on inflammatory cells (monocytes, macrophages, 
granulocytes), the number of CD63-positive (CD63+) cells per 
microscopic field was determined. Also, haematoxylin-eosin stained 
tumour sections were histologically examined for overall proportion of 
necrosis (%) and microvascular proliferations (MP; low, medium, high). 
Finally, CD63 expression was correlated with patients overall survival. 
Results: Immunohistochemical parameters were examined by 2 
independent researchers whose results were in good accordance 
(R=0.8, p<0.0001). The number of CD63+ inflammatory cells per 
microscopic field was 62.1±23.1 (mean±SD). A significant association 
was found between the number of CD63+ cells and the proportion of 
necrosis (p=0.004). Also, a correlation between the number of CD63+ 
cells and the proportion of MP was detected (p=0.009). Median 
survival time of the study group was 10.0 months (95% CI 9.0-11.0). 
However, the survival time clearly depended on the number of CD63+ 
cells in GBM tissue (log rank test, p=0.003). Median survival times for 
patients with low (less than median) and high (equal or more than 
median) number of CD63+ cells were 9.0 months (95% CI 8.1-9.9) and 
12.0 months (95% CI 8.5-15.5) respectively. In multivariate analysis, 
the number of CD63+ cells emerged as a significant independent 
predictor for longer overall survival (HR 2.4, 95% CI 1.2-5.1, p=0.02). 
Conclusions: Present study revealed a beneficial role of inflammation 
on survival of GBM patients. In patients with higher number of CD63+ 
cells prior radiotherapy, significantly longer survival times were 
achieved. Additionally, inflammatory reaction was associated with 
tumour micromilieu: there were more inflammatory cells in the 
presence of high proportion of necrosis and MP. Clearly, more studies 
are needed to evaluate the role of inflammation and tumour 
microenvironment on GBM treatment outcome. 
This work was supported by Institutional Research Funding 
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Purpose/Objective: Re-irradiation has been shown to be an option for 
recurrent high-grade glioma patients with proven but limited efficacy. 
Furthermore, bevacizumab exerts certain efficacy in combination with 
chemotherapy or as monotherapy and was safely tested in 
combination with radiotherapy for re-treatment in smaller studies. 
This report gives an update on the outcome of patients treated at the 
University hospital of Munich. To our knowledge, this is the largest 
cohort including patients treated with both re-irradiation and 
bevacizumab to date. 
Materials and Methods: After receiving standard radiotherapy (with or 
without TMZ) patients with recurrent malignant glioma were treated 
with bevacizumab (10mg/kg intravenously at d1 and d15) during re-
irradiation. Median prescribed radiation dose during re-treatment was 
36Gy, conventionally fractionated. 
Results: 71 patients re-irradiated in a single institution were 
retrospectively analyzed. Patients either received bevacizumab 
(N=57), other substances (N=4) or radiation alone (N=10). Re-
irradiation was tolerated well regardless of the additional therapy. In 
one patient with bevacizumab a wound dehiscence occurred, one 
patient suffered from deep vein thrombosis resulting in pulmonary 
embolism. One patient died of a perforated sigma diverticulitis. Post-
recurrence survival was significantly increased in patients receiving 
bevacizumab (p=0.003, log-rank test) as well as progression-free 
survival (p=0.005, log-rank test). KPS, surgery, MGMT, sex, WHO grade 
and age showed no statistically significant improvement in neither PFS 
nor survival. 
Conclusions: Re-irradiation with bevacizumab remains a feasible and 
highly effective treatment schedule. Studies on further salvage 
strategies and timing of sequential treatment options vs. observation 
are warranted.  
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Purpose/Objective: In order to define new prognostic subgroups in 
patients with glioblastoma (GBM) a method is presented how to derive 
potentially prognostic miRNA patterns employing a large screen (> 
1,200 miRNAs) from paraffin tissues including associated 
methodological problems and pitfalls. 
Materials and Methods: Thirty-six GBM patients treated in a single 
institution basically according to the EORTC/NCIC protocol between 
1/2009 - 12/2010 were included in this retrospective analysis. For 
microarray analysis, the febit biochip 'Geniom® Biochip MPEA homo 
sapiens' was used. Total RNA was isolated from FFPE slides, altogether 
over 1,200 different miRNAs were analyzed. In order to define 
significant patterns, a Cox regression analysis for each single miRNA 
was performed using long-term survival (split at 450 days) as censor; 
significant miRNAs (without multiple-testing correction) were chosen 
and a hierarchical clustering analysis was performed; survival of the 
